Promega is a major life sciences technology company with a portfolio of 4,000+ products, operations through branches in 16 countries, and more than 50 global distributors. Its customers include pharmaceutical and biotechnology companies, academic institutions, clinical laboratories, government organizations and research laboratories.
In qPCR and digital PCR, Promega’s strategy is increasingly moving beyond individual PCR reagents toward integrated molecular workflows, combining sample preparation, amplification, quantification and application-specific solutions.
Track leading companies, their investments, pipeline, sales, consumer behaviour and strategic moves to plan your next move. Download Sample: https://www.towardshealthcare.com/download-sample/5711
What Promega Is Doing
Promega has a strong established position in qPCR and RT-qPCR through its GoTaq portfolio, including dye-based and probe-based systems, one-step and two-step RT-qPCR solutions and workflows compatible with commonly used real-time PCR instruments.
Its published technical data includes 97% PCR efficiency and R² of 0.999 for a GoTaq 1-Step RT-qPCR experiment, while its GoTaq 2-Step RT-qPCR system has demonstrated a reported nine-order-of-magnitude linear dynamic range.
| Promega indicator | Data |
|---|---|
| Products | 4,000+ |
| Countries with branches | 16 |
| Global distributors | 50+ |
| R&D investment | 13.7% of revenue |
| Patents in reported period | 48 |
| Active patent portfolio | 442 |
Promega’s investment in R&D is particularly important because it indicates that the company is continuing to build technology rather than relying only on its established PCR portfolio.
Promega Is Building Around the PCR Workflow
One of Promega’s strongest strategic assets is its Maxwell nucleic-acid extraction portfolio.
This allows the company to participate before the PCR reaction itself:
Sample preparation → Nucleic-acid extraction → qPCR/dPCR → Downstream analysis
Promega’s extraction workflows support applications involving qPCR, digital PCR and NGS, giving the company an opportunity to sell a broader workflow rather than a single reagent.
This becomes particularly relevant in oncology, liquid biopsy, cell and gene therapy and molecular research, where sample quality and low-level target detection are critical.
The Countable Labs Partnership Is Important
In June 2026, Promega announced a co-marketing agreement with Countable Labs, combining Promega’s Maxwell nucleic-acid extraction technology with Countable’s single-molecule PCR technology.
Countable’s technology uses approximately 30 million compartments for single-molecule analysis. In a published plasma-derived cfDNA workflow, a multiplex KRAS assay achieved 0.08% mutant allele frequency for G12C after pre-amplification.
This gives Promega an additional route into applications requiring very high analytical sensitivity, particularly:
- Liquid biopsy
- Rare-variant detection
- Oncology research
- Cell and gene therapy
- Molecular diagnostics
The partnership is therefore more strategically important than a simple product collaboration. It potentially strengthens Promega’s position in high-sensitivity molecular analysis.
Promega’s Digital PCR Position
Promega’s position in digital PCR is different from its qPCR position.
The company has strong dPCR-compatible reagents, sample preparation and application workflows, but does not have the same proprietary instrument ecosystem as some major dPCR companies.
Its TruTiter Reagent System, for example, supports AAV genome quantification using qPCR or dPCR and is designed to eliminate the need for DNase treatment in the workflow.
This connects Promega to an important customer group: cell and gene therapy developers that require reliable viral-vector quantification.
The strategic question for Promega is whether it should continue building primarily around reagents and workflows or move further toward complete digital PCR platform ownership.
Who Promega Is Selling To
Promega’s buyers are not one homogeneous group. Each customer has different requirements.
Pharma companies
Pharma R&D and analytical teams typically look for:
- Reproducible results
- Validated workflows
- Automation
- High throughput
- Strong technical documentation
- Consistent reagent performance
- Integration with existing laboratory systems
Biotech and cell & gene therapy companies
These customers are more likely to prioritize:
- High sensitivity
- Low-copy detection
- AAV quantification
- Rare-target analysis
- Flexible workflows
- Faster development cycles
- Scalable analytical methods
Oncology and molecular laboratories
Their requirements can include:
- ctDNA analysis
- Rare mutation detection
- Liquid biopsy workflows
- Low-input DNA analysis
- FFPE sample processing
- Reproducibility
Research laboratories
They generally value:
- Ease of use
- Broad assay compatibility
- Instrument compatibility
- Cost efficiency
- Technical support
- Flexible experimental workflows
The important point for Promega is that the buyer is purchasing a reliable analytical workflow, not simply PCR chemistry.
What Buyers Are Looking For
Across these customer groups, several requirements repeatedly influence technology selection.
Sensitivity: Ability to detect low-abundance targets.
Specificity: Reliable discrimination between target and background.
Reproducibility: Consistent results across operators and experiments.
Throughput: Ability to process increasing sample volumes.
Automation: Less manual handling and fewer workflow steps.
Compatibility: Ability to use existing instruments and laboratory infrastructure.
Sample flexibility: Performance with plasma, FFPE, viral samples and other challenging inputs.
Ease of use: Simple protocols and reduced troubleshooting.
Total cost per result: Buyers increasingly consider labor, failed reactions and repeat testing—not only reagent price.
This creates an opportunity for Promega to position itself around workflow efficiency and reliability, rather than competing only on individual PCR products.
What Promega’s Competitors Are Doing
The competitive landscape becomes particularly important in digital PCR.
Bio-Rad
Bio-Rad has built one of the strongest dedicated digital PCR positions.
In 2025, Bio-Rad completed its acquisition of Stilla Technologies, expanding its digital PCR capabilities and subsequently rolling out the QX Continuum and QX700 series alongside its existing platforms.
Bio-Rad reported approximately $2.6 billion in 2024 revenue and around 7,700 employees.
Its QX700 systems support seven-color multiplexing, while Bio-Rad has also highlighted a portfolio of more than 400,000 assays.
The strategic advantage is clear:
Instrument + consumables + assays + installed base + application ecosystem.
Thermo Fisher Scientific
Thermo Fisher is taking a different approach through its QuantStudio Absolute Q digital PCR platform.
The system uses 20,480 microchambers per reaction, integrates partitioning and thermal cycling, and Thermo Fisher reports results in under 90 minutes for applicable workflows.
Its applications include:
- Cell and gene therapy
- Viral-vector analysis
- Liquid biopsy
- Rare-variant detection
- Molecular research
Thermo Fisher’s strength is its ability to combine instrumentation, reagents, assays, software and laboratory workflow integration.
Contact us for more: https://www.towardshealthcare.com/contact-us
What the Competitive Data Means for Promega
| Company | Main strength | Strategic direction |
|---|---|---|
| Promega | PCR chemistry + extraction + molecular workflows | Build broader integrated workflows |
| Bio-Rad | Digital PCR instruments + assays | Expand dPCR platform and application ecosystem |
| Thermo Fisher | Integrated instruments + assays + workflow | Simplify and scale dPCR adoption |
| Countable Labs | High-sensitivity single-molecule PCR | Rare-target and low-abundance detection |
Promega therefore faces a specific strategic challenge.
Its competitors can increasingly offer customers an end-to-end digital PCR ecosystem, while Promega has an opportunity to differentiate through its broader molecular biology and sample-preparation capabilities.
What Promega Should Focus On
Promega already has several assets that can be connected more strategically.
Strengthen digital PCR
Promega could use partnerships, licensing or acquisitions to deepen its digital PCR capabilities without necessarily building an entire platform internally.
Own the high-sensitivity workflow
The Countable Labs relationship provides an entry point into rare-variant and low-abundance detection.
Promega could expand around:
- Liquid biopsy
- ctDNA
- Rare mutations
- Oncology biomarkers
- MRD research
- Cell and gene therapy analytics
Expand cell and gene therapy applications
Its TruTiter AAV quantification capability provides a foundation for building deeper workflows around viral-vector characterization and analytical testing.
Convert existing qPCR customers
Promega already has a large qPCR customer base.
A key strategic opportunity is to create a clear pathway:
qPCR → higher-sensitivity analysis → dPCR → advanced molecular workflows
This could help retain customers as their analytical requirements become more sophisticated.
Sell complete workflows
Promega’s strongest differentiation may ultimately come from combining:
Maxwell + GoTaq + dPCR-compatible workflows + application-specific assays + technical support.
Instead of selling one product at a time, Promega can position itself as a solution for the customer’s complete molecular analysis problem.
Where Towards Healthcare Can Help You
For pharma, biotech and life sciences leaders, understanding Promega requires more than tracking its product launches.
Towards Healthcare Research & Consulting evaluates companies through the intelligence leaders need for strategic decisions.
We can provide:
Company intelligence
Investments, R&D activity, product launches, partnerships, acquisitions and strategic priorities.
Competitor intelligence
What Bio-Rad, Thermo Fisher, QIAGEN and other relevant companies are developing, investing in and launching.
Buyer intelligence
Who is purchasing qPCR and dPCR technologies, what applications they are using them for and what problems they need solved.
Consumer/user needs
Sensitivity, reproducibility, throughput, automation, ease of use, sample compatibility and cost per result.
Technology intelligence
qPCR, dPCR, sample preparation, rare-variant detection, AAV quantification and emerging molecular-analysis technologies.
Strategic consulting
Where the company is strong, where competitors are ahead, where customer needs are changing and what the company should do next.
The objective is not simply to answer “What is Promega doing?”
It is to connect:
What Promega is doing + what competitors are doing + what buyers need + where the technology is moving = what pharma and biotech leaders should do next.
That is the intelligence Towards Healthcare Research & Consulting brings to strategic decision-making.
You can also Email us at: [email protected]